Skip to Content

Yes to Adjuvant Chemotherapy in EGFR Mutated NSCLC

During ELCC23, a controversial session was held where opponents debated the efficacy of adjuvant chemotherapy for patients with EGFR-mutated NSCLC. Listen to the ”YES” opponent Benjamin Besse from the Gustave Roussy Cancer Campus in France, summarizing his arguments from the session in favor of adjuvant chemotherapy.

Benjamin Besse

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top